| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000261766.1 |
ABT-263 (navitoclax) |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
0.036214131 |
Resistant |
| ENSG00000261766.1 |
ABT-263 (navitoclax) |
Chronic Lymphocytic Leukemia |
0.017722816 |
Resistant |
